Histamine and Bradykinin Pharmacology

Correct Answer

B — Diphenhydramine

Rationale

Diphenhydramine is the prototype first-generation H1 antihistamine. Loratadine, fexofenadine, and cetirizine are all second-generation H1 antihistamines, distinguished by their minimal central nervous system penetration and once-daily dosing.

Correct Answer

A — Loratadine

Rationale

Loratadine is a second-generation H1 antihistamine. Diphenhydramine, hydroxyzine, and promethazine are all first-generation H1 antihistamines, characterized by significant central nervous system penetration and sedation.

Correct Answer

C — Famotidine

Rationale

Famotidine is an H2 receptor blocker. Omeprazole is a proton pump inhibitor, not an H2 blocker. Diphenhydramine is a first-generation H1 antihistamine. Ranitidine was an H2 blocker but was withdrawn from the market in 2020 due to N-nitrosodimethylamine contamination and is no longer available.

Correct Answer

D — Pitolisant

Rationale

Pitolisant is an H3 receptor inverse agonist approved for narcolepsy. By blocking the presynaptic H3 autoreceptor, it disinhibits histaminergic neurons of the tuberomammillary nucleus, promoting wakefulness. Modafinil promotes wakefulness through a different mechanism. Cetirizine and loratadine are second-generation H1 antihistamines with no H3 activity.

Correct Answer

A — Epinephrine

Rationale

Epinephrine is a non-selective adrenergic agonist, activating alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors. Propranolol is a non-selective beta-adrenergic antagonist. Diphenhydramine is a first-generation H1 antihistamine. Famotidine is an H2 receptor blocker.

Correct Answer

B — Vancomycin

Rationale

Vancomycin is a direct mast cell activator: rapid intravenous infusion triggers non-immunological histamine release, producing Red Man Syndrome. This reaction does not require prior sensitization and is not immunoglobulin E-mediated. Penicillin causes immunoglobulin E-mediated reactions requiring prior sensitization. Loratadine is a second-generation H1 antihistamine. Morphine also causes non-immunological histamine release, making it a strong distractor — both vancomycin and morphine share this property, but vancomycin is the agent most classically associated with the non-immunological direct mast cell activation classification in clinical teaching.

Correct Answer

C — Gq coupling — activates phospholipase C and raises intracellular calcium

Rationale

The H1 receptor couples to the Gq protein, which activates phospholipase C to generate inositol trisphosphate and diacylglycerol, raising intracellular calcium. Option A describes the H2 receptor, which couples to Gs and raises cyclic adenosine monophosphate. Option B describes the H3 receptor, which couples to Gi and acts as a presynaptic autoreceptor. Option D conflates H2 receptor signaling with its downstream effect on the proton pump in gastric parietal cells.

Correct Answer

A — Gs coupling — raises cyclic adenosine monophosphate, activates protein kinase A, stimulates the proton pump

Rationale

The H2 receptor couples to the Gs protein, activating adenylyl cyclase to raise cyclic adenosine monophosphate. This activates protein kinase A, which in turn activates the hydrogen-potassium ATPase (proton pump) to drive gastric acid secretion. Option B describes H1 receptor signaling via Gq. Option C describes H3 receptor signaling via Gi. Option D is internally inconsistent — Gs raises cyclic adenosine monophosphate but does not activate phospholipase C, which is a Gq-mediated event.

Correct Answer

D — Blockade of H1 receptors on histaminergic neurons of the tuberomammillary nucleus, suppressing cortical arousal

Rationale

First-generation antihistamines are lipophilic and readily cross the blood-brain barrier. Once in the central nervous system, they block H1 receptors on histaminergic neurons projecting from the tuberomammillary nucleus, which are active during wakefulness and normally promote cortical arousal. Suppressing this histaminergic tone produces sedation. Second-generation antihistamines are substrates for P-glycoprotein efflux transporters and do not achieve significant central nervous system concentrations, which accounts for their reduced sedating effect. First-generation antihistamines do have significant antimuscarinic activity in the central nervous system, which can contribute to cognitive slowing and confusion — particularly in elderly patients — but the primary mechanism of sedation is H1 receptor blockade at the tuberomammillary nucleus, not muscarinic blockade. H2 receptors do not mediate arousal or sedation. H3 blockade disinhibits histaminergic release rather than suppressing it.

Correct Answer

B — Inverse agonists preferentially stabilize the inactive receptor conformation, suppressing constitutive receptor activity

Rationale

An inverse agonist stabilizes the inactive state of a receptor, reducing activity below baseline — including any constitutive (histamine-independent) activity. A competitive antagonist occupies the binding site and blocks agonist access but does not change the baseline activity of the receptor in the absence of agonist. For practical clinical purposes, both produce the same outcome at the H1 receptor: blockade of histamine-mediated allergic responses. The inverse agonist distinction is mechanistically precise but does not change how these drugs are used clinically. Irreversible binding describes a different pharmacological category; H1 antihistamines are reversible. Partial agonism describes a drug that activates the receptor to a submaximal degree, which is the opposite of what inverse agonists do.

Correct Answer

A — Direct ionic displacement of histamine from mast cell granules, independent of immunoglobulin E

Rationale

Morphine and codeine directly displace histamine from its ionic binding to heparin proteoglycans within mast cell secretory granules. This non-immunological mechanism does not require prior sensitization and can occur on first exposure. The resulting local histamine release produces cutaneous flushing, whealing, and pruritus at the injection site. Because this is not immunoglobulin E-mediated, it is classified as an anaphylactoid-type reaction. Immunoglobulin E-mediated degranulation requires a sensitization exposure followed by re-exposure to the same antigen. Complement-mediated degranulation via C3a and C5a occurs in transfusion reactions and immune complex disease, not with opioid administration. Inhibition of histamine catabolism is not a mechanism by which any clinically used drug raises tissue histamine levels acutely.

Correct Answer

C — Anaphylaxis is a multimediator syndrome; antihistamines address only histamine-mediated components and cannot reverse vasodilation, bronchoconstriction, or hemodynamic collapse

Rationale

Systemic anaphylaxis involves massive release of histamine alongside prostaglandins, leukotrienes, platelet-activating factor, and tryptase. While antihistamines reduce histamine-mediated cutaneous manifestations such as urticaria and pruritus, they have no effect on the hemodynamic collapse or bronchospasm driven by these other mediators. Epinephrine simultaneously reverses vasodilation via alpha-1 adrenergic receptors, reverses bronchoconstriction via beta-2 adrenergic receptors, and supports cardiac output via beta-1 adrenergic receptors — addressing the multisystem emergency that antihistamines cannot. H1 antihistamines are selective for the H1 receptor and have no activity at adrenergic receptors that would allow them to restore vascular tone or relieve bronchospasm. The multimediator nature of anaphylaxis is the pharmacological basis for classifying antihistamines as adjunctive rather than first-line treatment.

Correct Answer

B — Histamine acts as a paracrine mediator released locally onto adjacent parietal cells, serving as the final common amplifier for all three stimulatory inputs

Rationale

Enterochromaffin-like cells are stimulated by gastrin and acetylcholine to release histamine in a paracrine fashion directly onto adjacent gastric parietal cells. Histamine then activates H2 receptors on those parietal cells, raising cyclic adenosine monophosphate and activating protein kinase A, which drives the proton pump. Because both gastrin and acetylcholine act partly through stimulating histamine release from enterochromaffin-like cells, histamine functions as the final common amplifier of gastric acid secretion — the pharmacological basis for H2 blocker therapy. Paracrine signaling acts locally within a tissue, not via systemic circulation. Parietal cells express H2 receptors, not H1 receptors. Enterochromaffin-like cells release histamine onto parietal cells; they are not the targets of the H2 receptor signaling cascade.

Correct Answer

D — Immunoglobulin E-mediated degranulation requires prior sensitization to generate drug-specific immunoglobulin E antibodies that arm mast cells; crosslinking by the drug on re-exposure triggers degranulation

Rationale

True immunoglobulin E-mediated anaphylaxis is a two-exposure process. On first exposure, genetically susceptible individuals produce drug-specific immunoglobulin E antibodies that bind to high-affinity immunoglobulin E receptors on mast cells and basophils, arming them. On re-exposure, the drug crosslinks adjacent receptor-bound immunoglobulin E molecules, triggering rapid granule-plasma membrane fusion and release of histamine and other mediators. Because the sensitization step cannot have occurred without a prior exposure, first-exposure reactions are classified as anaphylactoid — non-immunoglobulin E-mediated — even when the clinical syndrome is identical. Both types are managed identically with epinephrine as first-line treatment. Complement fragments C3a and C5a are anaphylatoxins that can themselves trigger mast cell degranulation; they do not block immunoglobulin E binding. High-affinity immunoglobulin E receptors are constitutively expressed on mast cells. Immunoglobulin E is produced by plasma cells derived from B lymphocytes, not by basophils.

Correct Answer

A — Inhibition of angiotensin converting enzyme reduces bradykinin degradation, causing bradykinin accumulation and increased submucosal vascular permeability

Rationale

Angiotensin converting enzyme (kininase II) is the principal enzyme responsible for bradykinin degradation. When angiotensin converting enzyme is inhibited by lisinopril, bradykinin accumulates and activates B2 receptors on vascular endothelium, producing submucosal edema through increased vascular permeability. This form of angioedema occurs without urticaria — because bradykinin, not histamine, mediates the permeability increase. The absence of urticaria in this case distinguishes it from histamine-mediated angioedema. Angiotensin converting enzyme inhibitor-induced angioedema can occur at any point during therapy, even after years of tolerance, and does not respond to epinephrine, antihistamines, or corticosteroids. The patient should be switched to an angiotensin receptor blocker permanently. Amlodipine causes ankle edema through arteriolar dilation, not oropharyngeal angioedema.

Correct Answer

C — Direct non-immunological mast cell activation by vancomycin, causing histamine release in a rate-dependent fashion without prior sensitization

Rationale

Rapid intravenous infusion of vancomycin causes direct, non-immunological activation of mast cells, producing Red Man Syndrome — flushing and erythema over the face, neck, and upper chest from local histamine release. The reaction is rate-dependent: it occurs when vancomycin is infused too rapidly, not as a function of dose in the immunological sense. Because no prior sensitization is required, this reaction can occur on the first vancomycin exposure, as in this case. Management involves slowing the infusion rate and premedication with H1 antihistamines before future infusions. The absence of prior vancomycin exposure makes immunoglobulin E-mediated anaphylaxis mechanistically impossible here. Complement-mediated degranulation is not the established mechanism for vancomycin reactions. Vancomycin does not inhibit histamine-catabolizing enzymes.

Correct Answer

B — Reduction of histamine-mediated cutaneous manifestations including urticaria and pruritus, as an adjunct after hemodynamic stabilization by epinephrine

Rationale

H1 antihistamines such as diphenhydramine reduce the histamine-mediated cutaneous components of anaphylaxis — urticaria, pruritus, and flushing — by blocking H1 receptors on vascular endothelium and sensory fibers. Their role in anaphylaxis management is strictly adjunctive: epinephrine must be given first to reverse hemodynamic collapse and bronchospasm, which are multimediator events that antihistamines cannot address. H1 antihistamines do not produce meaningful bronchodilation in the context of acute anaphylaxis. H1 antihistamines have no effect on prostaglandin or leukotriene synthesis — those pathways are inhibited by cyclooxygenase inhibitors and leukotriene antagonists, respectively. H1 antihistamines are receptor blockers and do not stabilize mast cell membranes or prevent ongoing degranulation.

Correct Answer

D — The presence of urticaria indicates histamine-mediated angioedema; treatment with epinephrine and antihistamines is expected to be effective

Rationale

Histamine-mediated angioedema occurs almost always in the context of urticaria, because histamine activates H1 receptors on both vascular endothelium (producing plasma extravasation and angioedema) and sensory C fibers (producing pruritus and urticaria). The concurrent urticaria signals histamine as the mediator and predicts that this reaction will respond to epinephrine and antihistamines. Bradykinin-mediated angioedema — from angiotensin converting enzyme inhibitors or hereditary angioedema — characteristically occurs without urticaria, because bradykinin does not activate the sensory pathways that produce the urticarial wheal-and-flare response. In bradykinin-mediated angioedema, epinephrine, antihistamines, and corticosteroids are ineffective. The absence of medication use and the acute allergen-triggered onset in this case are consistent with immunoglobulin E-mediated anaphylaxis, not with hereditary angioedema or angiotensin converting enzyme inhibitor-induced disease.